【医脉通-指南】2015+AHPBA专家共识声明：胆囊癌.pdfVIP

DOI:10.1111/hpb.12444 HPB ORIGINAL ARTICLE Gallbladder Cancer: expert consensus statement Thomas A. Aloia1, Nicolas Jarufe 2, Milind Javle3, Shishir K. Maithel4, Juan C. Roa5, Volkan Adsay6, Felipe J. F. Coimbra7 William R. Jarnagin8 1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2 Department of Digestive Surgery, School of Medicine, Catholic University of Chile (Ponti?cia Universidad Catolica de Chile), Santiago, Chile, 3Department of GI Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA, 4Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA, 5Department of Digestive Surgery, School of Medicine, Catholic University of Chile (Ponti?cia Universidad Catolica de Chile), Santiago, Chile, 6Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, GA, USA, 7Department of Abdominal Surgery, AC Camargo Cancer Centre, Sao~ Paulo, Brazil, and 8Department of Surgery, Memorial Sloan–Kettering Cancer Center, New York, NY, USA Abstract An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallblad- der carcinoma in order to establish practice guidelines. In summary, within high incidence areas, the assessment of routine gallbladder specimens should include the microscopic evaluation of a minimum of three sections and the cystic duct margin; specimens with dysplasia or proven cancer should be exten- sively sampled. Provided the patient is medically ?t for surgery, data support the resection of all gallblad- der polyps of 1.0 cm in diameter and those with imaging evidence of vascular stalks. The minimum staging evaluation of patients with suspected or proven gallbladder canc